.png){kind=icon}
.png){kind=icon}
Return
Structural signature of plasma proteins classifies the status of Alzheimer’s disease
.png){kind=icon}
OA
AI
DOI：10.1038/s43587-026-01078-2.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Alzheimer’s disease (AD) involves proteostasis dysregulation causing protein misfolding, but whether these structural changes manifest as plasma conformational biomarkers remains unclear. We profiled plasma protein structures from 520 participants including individuals with AD, individuals with mild cognitive impairment (MCI) and healthy controls. Using mass spectrometry and machine learning, we systematically characterized the structural proteome changes associated with ApoE variations and neuropsychiatric symptoms to identify AD-specific signatures. We developed a diagnostic panel using peptides from C1QA, CLUS and ApoB representing AD-associated structural changes. This three-marker panel achieved 83.44% accuracy in three-way classification (healthy versus MCI versus AD). Binary classification yielded area under the receiver operating characteristic curves of 0.9343 for healthy versus MCI and 0.9325 for MCI versus AD. Longitudinal samples were classified with 86.0% accuracy. This multi-marker panel based on plasma protein structural alterations represents a promising diagnostic approach that may enhance early AD detection and provide insights for clinical trials, improving therapeutic outcomes. Son et al. profile plasma protein structural changes to identify potential conformational biomarkers of Alzheimer’s disease. They report that disease progression, genotype and sex influence structure, and develop a diagnostic panel that tracks disease status.
Keywords:
Ageing
Biomarkers
Dementia
Life Sciences
general
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
19.4
Papers:
1.2K
Citations:
6.4K
View more organizations